Positive
●
Proactive Investors
●
3 months ago
Abivax SA (NASDAQ:ABVX, EPA:ABVX, FRA:2X10, FRA:2X1) shares surged more than 40% on Tuesday after the French biotech released updated safety data from its late-stage ulcerative colitis program for its investigational drug obefazimod, easing earlier market concerns around reported cancer cases in the study. The company said the additional analysis showed that observed malignancy rates across its...